As artificial intelligence continues to reshape the pharmaceutical landscape, VERAXA Biotech AG (NASDAQ: VRXA) is positioning itself at the forefront of precision oncology by integrating AI into its drug discovery process. The company was recently featured in an article highlighting its collaboration with Ardigen, an AI-focused research organization, to strengthen its oncology pipeline by leveraging AI to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates (ADCs).
VERAXA’s proprietary BiTAC(R) platform, which stands for Bispecific T-cell Activating Constructs, is designed to create therapies that require the presence of two cancer-associated targets on the same cell to activate. This “AND-gated” approach aims to increase specificity and reduce off-target effects, a common challenge in cancer treatment. By combining Ardigen’s expertise in AI, computational biology, and bioinformatics with VERAXA’s platform, the collaboration seeks to improve target validation and reduce development risks.
The integration of AI into drug discovery is not a new concept, but its application in identifying dual-target combinations is particularly promising. AI can analyze complex genomic, proteomic, and clinical datasets to predict which target pairs are most likely to yield effective and safe therapies. This capability is especially valuable for VERAXA’s AND-gated approach, which requires a nuanced understanding of tumor biology.
One of the most intriguing potential benefits of this collaboration is the ability to revisit historical clinical and preclinical data. Many therapies have been abandoned in the past due to toxicity concerns, but with AI’s ability to uncover new insights, some of these targets or therapies could be repurposed for safer applications. This could significantly expand the therapeutic arsenal against cancer without starting from scratch.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution for pioneering life science research. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T-cell engagers, bispecific ADCs, and other innovative formats. Its pipeline is guided by rigorous quality-by-design principles, and it aims to rapidly advance its candidates into clinical development.
The collaboration with Ardigen underscores the growing importance of AI in biotech, particularly in the field of precision oncology. By harnessing AI, VERAXA hopes to not only improve the efficacy of its therapies but also to bring them to market more efficiently. This could have significant implications for patients, as more targeted and safer cancer treatments become available.
For more information on VERAXA Biotech, visit the company’s newsroom at https://ibn.fm/VRXA or their website at www.VERAXA.com. The full article can be viewed at https://ibn.fm/2U2hQ.
